Edward Gudaitis - Acerus Pharmaceuticals President CEO, Director
| ASPCFDelisted Stock | USD 0.22 0.00 0.00% |
CEO
Mr. Edward Gudaitis serves as President, Chief Executive Officer, Director of the Company effective May 1, 2018. Mr. Gudaitis has spent over 20 years in the pharmaceutical industry. He has extensive experience in specialty markets such as Oncology, Hepatitis, HIV, CNS and Transplantation. His functional experience spans Country leadership, Business Unit Leadership, Marketing and Sales Management, Market Access, Pricing, Health Economics and Clinical Research. Mr. Gudaitis is best known for his role as General Manager for Gilead Sciences Canada Inc. where he was responsible for leading Gilead Canadian affiliate from startup in 2005 to one of the largest pharmaceutical companies in Canada in 2015 with sales of over 1 billion. He also led the launch of two significant products in the US market for Gilead as Senior Director, Marketing for Gilead US HIV Business. Prior to Acerus, Mr. Gudaitis served as Vice President and General Manager of Allergan Canada where he led a significant portfolio optimization process and leadership transformation. Earlier in his career he spent more than 10 years at HoffmannLa Roche in roles of increasing responsibility since 2018.
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 416 679 0771 |
| Web | https://www.aceruspharma.com |
Acerus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.541) % which means that it has lost $0.541 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (22.4197) %, meaning that it generated substantial loss on money invested by shareholders. Acerus Pharmaceuticals' management efficiency ratios could be used to measure how well Acerus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Acerus Pharmaceuticals has accumulated 21.14 M in total debt with debt to equity ratio (D/E) of 2.61, implying the company greatly relies on financing operations through barrowing. Acerus Pharmaceuticals has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Acerus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Acerus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acerus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acerus to invest in growth at high rates of return. When we think about Acerus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 7 records | CEO Age | ||
| Guillaume Rutten | Amkor Technology | 68 | |
| Bharat Masrani | Toronto Dominion Bank | 68 | |
| Gregory Braca | Toronto Dominion Bank | N/A | |
| William McDermott | ServiceNow | 63 | |
| Riaz Ahmed | Toronto Dominion Bank | N/A | |
| Kenneth Lalonde | Toronto Dominion Bank | N/A | |
| Leovigildo Salom | Toronto Dominion Bank | N/A | |
Management Performance
| Return On Equity | -22.42 | |||
| Return On Asset | -0.54 |
Acerus Pharmaceuticals Leadership Team
Elected by the shareholders, the Acerus Pharmaceuticals' board of directors comprises two types of representatives: Acerus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acerus. The board's role is to monitor Acerus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Acerus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acerus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gavin Damstra, VP Commercial | ||
| Kevin Hickey, VP Commercial | ||
| FACE MD, Chief Officer | ||
| Chris Witty, Investor Relations | ||
| Edward Gudaitis, President CEO, Director | ||
| Hubert Czerwinski, Pres SRL | ||
| Philippe Savard, Gen VP | ||
| Naveed Manzoor, Interim Officer |
Acerus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Acerus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -22.42 | |||
| Return On Asset | -0.54 | |||
| Operating Margin | (8.41) % | |||
| Current Valuation | 49.66 M | |||
| Shares Outstanding | 7.71 M | |||
| Shares Owned By Insiders | 91.41 % | |||
| Price To Book | 20.08 X | |||
| Price To Sales | 2.16 X | |||
| Revenue | (4.13 M) | |||
| Gross Profit | 1 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Acerus Pharmaceuticals information on this page should be used as a complementary analysis to other Acerus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Acerus OTC Stock
If you are still planning to invest in Acerus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acerus Pharmaceuticals' history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |